Business Context and Reporting Period
Enlivex Therapeutics Ltd., an Israeli company, filed this Form 6-K on October 22, 2020, for the month of October 2020. The filing announces the entry into an At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC to facilitate the sale of ordinary shares.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new equity financing arrangement.
Material Changes
The primary material change is the authorization of a new equity offering mechanism. The Company may sell ordinary shares with an aggregate offering price of up to $25.0 million through the Sales Agent. Sales may occur via "at-the-market" offerings on the Nasdaq Capital Market or other permitted methods. The Company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Terms
- Offering Size: Up to $25.0 million in aggregate offering price.
- Commission: The Company agreed to pay the Sales Agent a commission of 3.0% of the gross sales price for each sale.
- Expenses: The Company will reimburse the Sales Agent for certain specified expenses related to the agreement.
- Termination: The agreement terminates upon the sale of all Offered Shares or earlier termination by either party.
- Registration: Sales will be made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-232009).
The filing text does not provide specific guidance on future financial performance, operational outlook, or risk factors beyond standard legal disclaimers regarding the offering.
Investor Verification Checklist
- Verify the current market price of Enlivex ordinary shares to assess potential dilution from the $25.0 million ATM facility.
- Review the full text of the ATM Agreement (Exhibit 10.1) for specific price limits or conditions the Company may impose on sales.
- Check subsequent filings to determine if and when the Company elects to sell shares under this agreement.
- Confirm the Company's current cash position and burn rate to understand the necessity of this financing option.